Fundraising FoxAbingworth — 2016 Investments
2 investments dated 2016 · listed companies and verified rows first · show all
IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.
BiotechHealthtechCambridge, US
Gary D. Glick(Founder)inH. Martin Seidel(Chief Executive Officer)in
BoardJean-Francois Formela(Director)in
Co-investorsAtlas Venture
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.